Bempegaldesleukin in combination with nivolumab for previously untreated unresectable or metastatic melanoma

Bempegaldesleukin in combination with nivolumab is in clinical development as a treatment option for previously untreated unresectable or metastatic melanoma. Melanoma is a type of skin cancer that can occur anywhere on the body and spread to other vital organs. Unresectable melanoma refers to cancers that cannot removed with surgery while metastatic melanoma is one that has spread from the primary site to other parts of the body. Due to poor tumour response, not all patients respond to the standard of care treatment (immune checkpoint inhibitors such as nivolumab) in previously untreated, unresectable or metastatic melanoma. Therefore, there is an unmet need for novel therapies that can achieve durable responses without adding substantial toxicity.